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Leptin has beneficial effects on glucose metabolism
via actions in the hypothalamus, but the roles of spe-
cific subgroups of neurons responsible for these
antidiabetic effects remain unresolved. We gener-
ated diabetic Lepob/ob or Leprdb/db mice lacking or
re-expressing leptin receptors (LepRb) in subgroups
of neurons to explore their contributions to leptin’s
glucose-lowering actions. We show that agouti-
related peptide (AgRP)-expressing neurons are
both required and sufficient to correct hyperglyce-
mia by leptin. LepRb in pro-opiomelanocortin
(POMC) neurons or steroidogenic factor-1 (SF1) neu-
rons are not required. Furthermore, normalization of
blood glucose by leptin is blunted in Lepob/ob/
MC4R-null mice, but not in Lepob/ob mice lacking
neuropeptide Y (NPY) or gamma-aminobutyric acid
(GABA) in AgRP neurons. Leptin’s ability to improve
glucose balance is accompanied by a reduction in
circulating glucagon. We conclude that AgRP neu-
rons play a crucial role in glucose-lowering actions
by leptin and that this requires the melanocortin
system, but not NPY and GABA.
INTRODUCTION
The adipocyte hormone leptin, besides its well-known effects on
body weight, also plays a key role in the control of glucose
homeostasis. Lepob/ob and Leprdb/db mice that lack leptin or its
receptors, respectively, are severely hyperglycemic and hyperin-
sulinemic (Chen et al., 1996; Coleman, 1978; Lee et al., 1996;
Spiegelman and Flier, 2001; Zhang et al., 1994), and the
glucose-lowering actions of leptin are independent of its effects
on body weight and caloric intake (Hedbacker et al., 2010;
Pelleymounter et al., 1995; Schwartz et al., 1996). In addition,
leptin therapy is effective to improve insulin sensitivity in mice
and humans suffering from lipodystrophy (Oral et al., 2002;
Petersen et al., 2002; Shimomura et al., 1999) and in a polyge-
netic rat model of late-onset obesity and type 2 diabetes (Cum-
mings et al., 2011). Rodent studies suggest that these beneficialCeffects of leptin are mediated by its actions in the brain, more
specifically by the hypothalamus (Coppari and Bjørbæk, 2012).
The arcuate nucleus of the hypothalamus (ARC) has been
shown to play a pivotal role in mediating the antidiabetic effects
of leptin in mice (Coppari et al., 2005). The ARC has two major
subsets of neurons that express leptin receptors: pro-opiomela-
nocortin (POMC) neurons that release a-melanocyte-stimulating
hormone (a-MSH), an anorexigenic neuropeptide that activates
the melanocortin receptor 3 and 4 (MC3R and MC4R), and
agouti-related peptide (AgRP)-expressing neurons that, in addi-
tion of being GABAergic, also releases the orexigenic neuropep-
tides AgRP (an antagonist of MC3R and MC4R) and neuropep-
tide Y (NPY) (Cone, 2005; Horvath et al., 1997; Ollmann et al.,
1997; Schwartz et al., 2000; Vong et al., 2011). Leptin promotes
its effects on body weight partly by activating POMC neurons
and inhibiting AgRP neurons (Balthasar et al., 2004; Cowley
et al., 2001; Huang et al., 2013; van den Top et al., 2004; van
de Wall et al., 2008). Recent evidence has demonstrated that
POMC neurons can serve a sufficient role in mediating antidia-
betic effects of leptin: re-expression of LepRb only in POMCneu-
rons normalizes the severe hyperglycemia of hyperleptinemic
Leprdb/db animals (Huo et al., 2009). However, the requirement
of POMC neurons to mediate antidiabetic effects by leptin in dia-
betic mice with physiological serum leptin levels has not been
investigated. In addition, animals lacking LepRb only in POMC
neurons are normoglycemic (Balthasar et al., 2004), suggesting
that other subsets of neurons also play a critical role in mediating
the beneficial glucose-lowering effects of leptin.
Of the diverse subgroups of neurons that express leptin recep-
tors within the hypothalamus, twomajor populations in particular
could be potential targets of leptin to mediate its antidiabetic
actions: (1) arcuate AgRP neurons; for example, AgRP neurons
were likely targeted in LepR-deficient mice where virally medi-
ated re-expression of LepRs in theARCcorrecteddiabetes (Cop-
pari et al., 2005), and (2) neurons within the ventromedial nucleus
of the hypothalamus (VMH); leptinmicroinjection into the VMH in-
creases glucose uptake in peripheral tissues (Minokoshi et al.,
1999), glutamatergic VMHneurons canact to prevent hypoglyce-
mia (Tong et al., 2007), and intra-VMH leptin delivery can rescue
diabetes in streptozotocin (STZ) diabetic rats (Meek et al., 2013).
To investigate the potential role of these different subsets of
neurons in leptin’s antidiabetic actions in both high and low
physiological levels of leptin, we generated diabetic mouseell Reports 7, 1093–1103, May 22, 2014 ª2014 The Authors 1093
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Figure 1. LepRb in AgRP Neurons, but Not
in SF1 Neurons, Are Sufficient in Mediating
Leptin’s Antidiabetic Actions
Body weight (A), glycemia (B), food intake
(9 weeks of age) (C), body composition (10–
12 weeks of age) (D), serum leptin (E), insulin (F),
and glucagon (12 weeks of age) (G) in HA-
LepRbflox, HA-LepRbflox/Leprdb/db, HA-LepRbflox/
SF1-cre/Leprdb/db, HA-LepRbflox/AgRP-ires-cre/
Leprdb/db, and HA-LepRbflox/Leprdb/db - PF male
mice. PF, pair-fed (5–12 weeks) to lean control
mice. Errors bars are shown as SEM (n = 5–8/
group). Statistical analyses were done using one-
or two-way ANOVA (Bonferroni post hoc ana-
lyses). *p < 0.05 HA-LepRbflox/AgRP-ires-cre/
Leprdb/db versus HA-LepRbflox/Leprdb/db mice;
**p < 0.05 HA-LepRbflox/SF1-cre/Leprdb/db or HA-
LepRbflox/AgRP-ires-cre/Leprdb/db versus HA-
LepRbflox/Leprdb/db mice. BW, body weight; n.s.,
not significant. See also Figures S1 and S2.models lacking or re-expressing leptin receptors only in selected
subgroups of hypothalamic neurons (i.e., AgRP, VMH, and
POMC). In addition, to identify downstream molecular media-
tors, we developed mice deficient in MC4Rs or NPY or
gamma-aminobutyric acid (GABA) release from AgRP neurons.
Collectively, our data show that AgRP neurons, but not VMH or
POMC neurons, are both sufficient and required to mediate the
glucose-lowering action of leptin and that this effect requires
the intact melanocortin system, but not NPY or GABA.
RESULTS
Sufficiency of AgRP, but Not VMH, Neurons in Mediating
Leptin’s Antidiabetic Actions
To determine if AgRP or VMH (steroidogenic factor-1 [SF1]) neu-
rons of the hypothalamus are sufficient in mediating leptin’s anti-1094 Cell Reports 7, 1093–1103, May 22, 2014 ª2014 The Authorsdiabetic actions, we generated Leprdb/db
mice that only express LepRb in AgRP
(hemagglutinin [HA]-LepRbflox/AgRP-
ires-cre/Leprdb/db) or SF1 (HA-LepRbflox/
SF1-cre/Leprdb/db) neurons using our
HA-LepRbflox transgenic mice, which
allow expression of LepRb in a cre-
dependent manner (Huo et al., 2009).
First, to verify the specificity of LepRb
expression, we measured leptin-depen-
dent STAT3 phosphorylation in the hypo-
thalamus of these mice. As expected,
phosphorylated STAT3 (pSTAT3) was
only found in the medial-ventral ARC
of HA-LepRbflox/AgRP-ires-cre/Leprdb/db
mice, thus matching the known anatom-
ical localization of AgRP/NPY neurons
(Figure S1A). In addition, the total number
of ARC pSTAT3 cells in HA-LepRbflox/
AgRP-ires-cre/Leprdb/db mice (n = 4,408)
was only slightly less than the total num-ber of humanized Renilla reniformis GFP (hrGFP)-positive neu-
rons (n = 4,784) in the ARC of NPY-hrGFP mice and the total
number of ARC NPY neurons as assessed by NPY in situ hybrid-
ization in wild-type mice (n = 5,200; Ha et al., 2013), indicating
that HA-LepRb was correctly targeted to the vast majority of
AgRP/NPY neurons and not expressed beyond the AgRP/NPY
neuronal population. In HA-LepRbflox/SF1-cre/Leprdb/db mice,
pSTAT3was detected only in the VMH as expected (Figure S1B),
thus altogether validating the expected expression pattern of
HA-LepRb in the two lines of transgenic Leprdb/db mice.
Both HA-LepRbflox/AgRP-ires-cre/Leprdb/db and HA-
LepRbflox/SF1-cre/Leprdb/db mice were slightly leaner compared
to HA-LepRbflox/Leprdb/db control mice (Figure 1A). Surprisingly,
despite being massively obese, food intake of HA-LepRbflox/
AgRP-ires-cre/Leprdb/db mice was reduced to wild-type levels
(Figure 1C). HA-LepRbflox/AgRP-ires-cre/Leprdb/db mice also
had slightly reduced fat mass compared to HA-LepRbflox/
Leprdb/db mice (Figure 1D). No effect on food intake or body
composition was observed in HA-LepRbflox/SF1-cre/Leprdb/db
mice compared to HA-LepRbflox/Leprdb/db mice (Figures 1C
and 1D). Remarkably, expression of HA-LepRb only in AgRP
neurons, but not in SF1 neurons, rescued the severe diabetes
observed in the male HA-LepRbflox/Leprdb/db mice (Figure 1B).
Similar results were found in HA-LepRbflox/AgRP-ires-cre/
Leprdb/db females (Figure S2A). Because genetic background
can affect glycemic phenotype, we also tested Leprdb/db mice
with the AgRP-ires-cre allele and found that also these mice
were equally diabetic, thus demonstrating that the background
of mice with the AgRP-ires-cre genotype is not a cause of nor-
moglycemia (not shown). Overexpression of HA-LepRb in SF1
or AgRP neurons of lean mice did not affect body weight or gly-
cemia (Figure S2B). To test if the normalization of the glucose
levels in HA-LepRbflox/AgRP-ires-cre/Leprdb/db mice could be
secondary to the reduced food intake, we pair fed (PF) HA-Lep-
Rbflox/Leprdb/db control mice to the food intake level of wild-type
mice from 5 to 12 weeks of age (Figure 1C). As shown in Fig-
ure 1B, this markedly reduced food intake of HA-LepRbflox/
Leprdb/db (PF) mice over the 7weeks did not attenuate the severe
hyperglycemia compared to that of ad libitum HA-LepRbflox/
Leprdb/db mice, demonstrating that the normalization of blood
glucose in HA-LepRbflox/AgRP-ires-cre/Leprdb/db mice was in-
dependent of their reduced food intake. These data suggest
that AgRP neurons, but not SF1 neurons, are sufficient to
mediate leptin’s antidiabetic actions, similar to what we have re-
ported earlier for POMC neurons (Huo et al., 2009).
As expected, leptin levels were greatly elevated in all groups of
Leprdb/db mice relative to lean HA-LepRbflox controls (Figure 1E).
To investigate if the near normalization of glycemia in HA-
LepRbflox/AgRP-ires-cre/Leprdb/db mice could be due to
changes in glucoregulatory hormones, we measured circulating
insulin and glucagon. Insulin was similar in HA-LepRbflox/AgRP-
ires-cre/Leprdb/db and HA-LepRbflox/SF1-cre/Leprdb/db mice
(Figure 1F). In contrast, serum glucagon levels were normalized
in HA-LepRbflox/AgRP-ires-cre/Leprdb/db, but not in HA-
LepRbflox/SF1-cre/Leprdb/db, mice compared to lean control
mice (Figure 1G). These data are consistent with the possibility
that reduced glucagon action plays an important role in the
normalization of blood glucose concentrations in HA-LepRbflox/
AgRP-ires-cre/Leprdb/db mice.
Requirement of AgRP Neurons, but Not POMC or VMH
Neurons, in Mediating Leptin’s Antidiabetic Actions
Next, to test the requirement of the different subsets of neurons
in mediating leptin’s antidiabetic actions, we generated
diabetic Lepob/ob mice lacking LepRb selectively in AgRP neu-
rons (LepRbfl/fl/AgRP-ires-cre/Lepob/ob mice), POMC neurons
(LepRbfl/fl/POMC-cre/Lepob/ob mice), or SF1 neurons (LepRbfl/fl/
SF1-cre/Lepob/ob mice). As expected, LepRbfl/fl/AgRP-ires-
cre/Lepob/ob, LepRbfl/fl/POMC-cre/Lepob/ob, and LepRbfl/fl/SF1-
cre/Lepob/ob were hyperglycemic to the same extent and had
similar body weight curves and food intake compared to
LepRbfl/fl/Lepob/ob control mice (Figures 2A–2C).
We then implanted subcutaneously osmotic pumps delivering
a low dose of leptin, which has previously been determined toCreduce glucose levels of diabetic Lepob/ob mice independently
of changes in body weight (Hedbacker et al., 2010). We show
that this rate of leptin delivery (25 ng/hr) to Lepob/ob mice results
in serum leptin levels that are comparable to that of normal wild-
type (WT) mice (Figure S3A).
At 8 weeks of age, minipumps were implanted (day 0) and
body weight, food intake, and serum glucose were recorded.
As shown in Figure 2D, leptin treatment did not affect body
weight but caused a modest reduction of food intake in all
groups (Figure 2E). As expected, leptin, but not PBS, treatment
normalized glucose levels of LepRbfl/fl/Lepob/ob control mice
after 2 or 3 days (Figure 2F). In addition, leptin fully corrected gly-
cemia of LepRbfl/fl/POMC-cre/Lepob/ob and LepRbfl/fl/SF1-cre/
Lepob/ob mice (Figure 2F). In contrast and remarkably, leptin
did not have any effect on glucose levels of LepRbfl/fl/AgRP-
ires-cre/Lepob/ob mice (Figure 2F). To rule out that the slightly
reduced food intake in the LepRbfl/fl/Lepob/ob, LepRbfl/fl/
POMC-cre/Lepob/ob, and LepRbfl/fl/SF1-cre/Lepob/ob mice rela-
tive to the LepRbfl/fl/AgRP-ires-cre/Lepob/ob mice could affect
the glycemic results, we food restricted a new group of diabetic
LepRbfl/fl/Lepob/ob control mice to 4 g/day (less than any group)
during 5 consecutive days. We found that this level of food
restriction had no impact on blood glucose levels (Figure 2G).
Collectively, these data suggest that AgRP neurons, but not
POMC or SF1 neurons, are required in mediating leptin’s antidi-
abetic actions.
Because the normalization of diabetes in LepRbflox/AgRP-
ires-cre/Leprdb/db mice correlated with normalization of serum
glucagon levels (Figure 1G), we also measured glucagon (and
insulin) acutely after low-dose leptin infusion (25 ng/hr) in dia-
betic Lepob/ob mice when glucose was normalized (Figure 2F).
As shown in Figures S3B and S3C, short-term, low-dose leptin
infusion fully corrected glucagon levels in Lepob/ob mice but did
not affect serum insulin. These data combined support the
notion that reduced glucagon action plays an important role in
the normalization of blood glucose concentrations by leptin
action via AgRP neurons.
Requirement of the Melanocortin System on Leptin’s
Antidiabetic Actions
We next aimed to identify the downstream effectors synthesized
in AgRP neurons that might be responsible for leptin’s antidia-
betic actions. First, we addressed the role of the AgRP peptide
indirectly (Krashes et al., 2013) by generating diabetic Lepob/ob
mice lacking MC4Rs (MC4R//Lepob/ob mice) and evaluating
leptin responsiveness on blood glucose levels. Deletion of
MC4R in MC4R//Lepob/ob mice did not affect body weight,
blood glucose, or body composition compared to control
Lepob/ob mice (Figures 3A, 3B, and 3D). However, despite having
similar body weights, MC4R//Lepob/ob mice ingested slightly
more food than Lepob/ob mice (Figure 3C). To assess leptin’s ef-
fects on glucose levels, we implanted subcutaneously osmotic
pumps (day 0) with the low-dose leptin (25 ng/hr) for 12 days.
As expected, body weight and food intake was similar in
MC4R//Lepob/ob and Lepob/ob mice (Figures 3E and 3F).
Notably, glucose improvement by leptin was entirely blunted in
diabetic MC4R//Lepob/ob mice compared to the normaliza-
tion-observed Lepob/ob control mice (Figure 3G). These dataell Reports 7, 1093–1103, May 22, 2014 ª2014 The Authors 1095
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Figure 2. LepRb in AgRP Neurons, but Not
in SF1 or POMC Neurons, Are Required in
Mediating Leptin’s Antidiabetic Actions
(A–C) Body weight (A), glycemia (B), and food
intake (7 weeks of age) (C) in LepRbfl/fl/Lepob/ob,
LepRbfl/fl/AgRP-ires-cre/Lepob/ob, LepRbfl/fl/POMC-
cre/Lepob/ob, and LepRbfl/fl/SF1-cre/Lepob/ob male
mice.
(D–F) Leptin infusion for 5 days: percent of initial
body weight (D), daily food intake (E), and glyce-
mia (F) in LepRbfl/fl/Lepob/ob - PBS (placebo
group), LepRbfl/fl/Lepob/ob, LepRbfl/fl/AgRP-ires-
cre/Lepob/ob, LepRbfl/fl/POMC-cre/Lepob/ob, and
LepRbfl/fl/SF1-cre/Lepob/ob male mice.
(G) Mice were food restricted (FR) to 4 g/day:
percent of initial body weight and glycemia in
LepRbfl/fl/Lepob/ob - FR male mice. Errors bars are
shown as SEM (n = 3–11/group). Statistical ana-
lyses were done using two-way ANOVA (Bonfer-
roni post hoc analyses). *p < 0.05 versus
LepRbfl/fl/Lepob/ob mice.
See also Figure S3.show that leptin’s beneficial action on glucose metabolism re-
quires an intact melanocortin effector system.
NPY Does Not Play a Role on Leptin’s Antidiabetic
Actions
To determine whether NPY, a neuropeptide known to be coex-
pressed and released by AgRP neurons (Hahn et al., 1998), plays
a potential role in the glucose-lowering actions of leptin, we
created diabetic Lepob/ob mice lacking NPY (NPY//Lepob/ob
mice). NPY//Lepob/ob mice showed similar body weight
curves, food intake, and hyperglycemia as the control NPY/+/
Lepob/ob mice (Figures 4A–4C). A slight decrease in fat mass per-
centage was observed in NPY//Lepob/ob mice compared to
NPY/+/Lepob/ob control mice (Figure 4D). Using the same1096 Cell Reports 7, 1093–1103, May 22, 2014 ª2014 The Authorsapproach as described above, we tested
the effects of low-dose leptin infusion
(25 ng/hr). Again, leptin did not signifi-
cantly affect body weight or food intake
(Figures 4E and 4F) but was able to fully
ameliorate diabetes of both study
NPY//Lepob/ob and control NPY/+/
Lepob/ob mice (Figure 4G). These results
show that NPY is not required in the
long-term development of hyperglycemia
observed in leptin-deficient mice and that
NPY does not play a role in leptin’s short-
term antidiabetic actions.
GABAReleased by AgRPNeurons Is
Not Required for Leptin’s
Antidiabetic Actions
Finally, we investigated whether the
neurotransmitter GABA, which is also
released by AgRP neurons (Horvath
et al., 1997; Vong et al., 2011), might influ-
ence glucose metabolism in Lepob/obmice and play a role in mediating leptin’s antidiabetic actions.
For this purpose, we generated diabetic Lepob/ob with condi-
tional knockout of the vesicular GABA transporter (VGAT),
required for presynaptic release of GABA, in AgRP neurons
(Vgatfl/fl/AgRP-ires-cre/Lepob/ob mice). Surprisingly, loss of
GABA from AgRP neurons in Lepob/ob mice did not affect body
weight, food intake, glycemia, or body composition compared
to Vgatfl/fl/Lepob/ob control mice (Figures 5A–5D). We then
measured effects of low-dose leptin (25 ng/hr) on glucose meta-
bolism. Leptin treatment did not affect body weight or food
intake (Figure 5E and 5F) and improved blood glucose levels to
a similar extent in both Vgatfl/fl/AgRP-ires-cre/Lepob/ob and
Vgatfl/fl/Lepob/ob control mice (Figure 5G). Therefore, GABA pro-
duced by AgRP neurons does not play a role in control of
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Figure 3. MC4Rs Are Required for Leptin’s
Antidiabetic Actions
(A–D) Body weight (A), glycemia (B), food intake
(9 weeks of age) (C), and body composition (9 or
10 weeks of age) (D) in Lepob/ob and MC4R//
Lepob/ob male mice.
(E–G) Leptin infusion for 12 days at 10 weeks of
age: percent of initial body weight (E), daily food
intake (F), and glycemia (G) in Lepob/ob and
MC4R//Lepob/ob male mice. Errors bars are
SEM (n = 3–13/group). Statistical analyses were
done using Student’s t test or two-way ANOVA
(Bonferroni post hoc analyses). *p < 0.05 versus
Lepob/ob mice.circulating glucose levels at baseline in Lepob/ob mice nor is
GABA derived from AgRP neurons required for the blood-
glucose-lowering effects by leptin therapy.
DISCUSSION
Leptin has potent effects on glucose metabolism though its ac-
tions in the hypothalamus. However, the neurochemical identity
of the neurons responsible for this effect and the downstream
mediators involved in these actions has remained unresolved.
Here, we applied genetics and pharmacology to investigateCell Reports 7, 1093–110these issues in obese diabetic mouse
models. We report that hypothalamic
AgRP neurons, but not POMC or
SF1 neurons, are both required and suffi-
cient in mediating leptin’s antidiabetic
actions. In addition, the ability of leptin
to normalize hyperglycemia does not
involve GABA derived from AgRP neu-
rons or NPY, but instead requires an
intact melanocortin-4 receptor system.
Furthermore, the correction of hypergly-
cemia by leptin resulted in a concomitant
normalization of hyperglucagonemia.
Combined, these data suggest the
existence and importance of a leptin-
LepRb-AgRP-MC4R-glucose axis in
which glucagon is the peripheral effector
hormone.
The beneficial effects of leptin on
glucose balance have been reported in
rodent models of type 1 and type 2 dia-
betes and in severely insulin-resistant
humans (Coppari and Bjørbæk, 2012;
Cummings et al., 2011). Studies in
mice suggest that these effects are
mediated by leptin’s direct actions in
the hypothalamus (Coppari et al., 2005;
Fujikawa et al., 2013). It is further re-
ported that LepRb signaling only in
POMC neurons within the ARC of the
hypothalamus is sufficient to rescue dia-
betes of Leprdb/db mice (Huo et al.,2009), indicating a role of POMC neurons. On the other hand,
because selective loss of LepRb in POMC neurons does not
lead to hyperglycemia (Balthasar et al., 2004), other neurons
in addition of POMC neurons must exist that also play impor-
tant roles in leptin’s antidiabetic actions. To identify such neu-
rons, we considered hypothalamic AgRP neurons and SF1
neurons as likely candidates, due to their anatomical localiza-
tion (ARC and VMH, respectively) and data suggesting roles
of these brain nuclei in leptin’s effect on peripheral glucose
balance (Coppari et al., 2005; Meek et al., 2013; Minokoshi
et al., 1999; Tong et al., 2008). To that end, we first selectively3, May 22, 2014 ª2014 The Authors 1097
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Figure 4. NPY Is Not Required for Leptin’s
Antidiabetic Actions
(A–D) Body weight (A), glycemia (B), food intake
(9 weeks of age) (C), and body composition (9 or
10 weeks of age) (D) in NPY+// Lepob/ob and
NPY// Lepob/ob male mice.
(E–G) Leptin infusion for 12 days at 10 weeks of
age: percent of initial body weight (E), daily food
intake (F), and glycemia (G) inNPY+//Lepob/ob and
NPY// Lepob/ob male mice. Errors bars are
shown as SEM (n = 3–7/group). Statistical
analyses were done using Student’s t test. *p <
0.05 versus NPY+//Lepob/ob mice.re-expressed LepRb in AgRP or SF1 neurons of diabetic
LepRb-deficient Leprdb/db mice to determine the sufficiency
of those cells to correct hyperglycemia by leptin. Second, we
selectively deleted LepRb in the same candidate neurons as
well as POMC neurons of diabetic leptin-deficient Lepob/ob
mice to determine the requirement of those cells in a model
of low-dose-leptin-induced normalization of circulating glucose
levels (Hedbacker et al., 2010). We found that LepRb in SF1/
VMH neurons was neither sufficient nor required for leptin to
reduce hyperglycemia. In stark contrast, LepRb expression in
AgRP neurons was both required and sufficient to mediate
leptin-dependent normalization of the severe diabetes in these1098 Cell Reports 7, 1093–1103, May 22, 2014 ª2014 The Authorsmice. These effects via AgRP neurons
were entirely independent of changes
in body weight, adipose tissue mass,
and energy intake. We further show
that LepRb in POMC neurons is not
required for leptin’s ability to correct
hyperglycemia in Lepob/ob mice, despite
the earlier studies showing the suffi-
ciency of POMC-LepRbs to prevent
diabetes in LepR-deficient mice (Ber-
glund et al., 2012; Huo et al., 2009).
We conclude that, although both AgRP
and POMC neurons are each sufficient
in mediating leptin’s glucose-lowering
actions in diabetic states, only AgRP
neurons are fully required for these ac-
tions, altogether suggesting that AgRP
neurons serve a crucial superior role
for leptin’s ability to ameliorate diabetes
in severe hyperglycemic states.
It is unclear how POMC neurons can
serve as sufficient mediators in Leprdb/db
mice to correct hyperglycemia but not
be required in the leptin-infusion para-
digm in Lepob/ob mice. One possibility
explaining the sufficiency is that the
high-circulating leptin levels (50–100-
fold versus WT) in Leprdb/db mice ex-
pressing LepRb selectively in POMC
neurons is able to drive POMC neurons
to produce very high levels of a-MSH,
which can overcome the known highexpression and release of the inhibitory AgRP peptide in
Leprdb/db mice, ultimately leading to activation of MC4Rs. The
lack of requirement of LepRb in POMC neurons in the Lepob/ob
setting could potentially be caused by the potency of low-dose
leptin to strongly inhibit release of AgRP from AgRP neurons,
allowing a leptin-independent tone of a-MSH release to acti-
vate MC4Rs. In contrast, in Lepob/ob mice lacking LepRb in
AgRP neurons, the stimulation of a-MSH expression/release
by POMC neurons by low-dose leptin may only be partial
and insufficient to overcome the high levels of AgRP neuropep-
tide, thus demonstrating the requirement of LepRb signaling in
AgRP neurons.
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Figure 5. GABA Released by AgRP Neurons
Is Not Required for Leptin’s Antidiabetic Ac-
tions
(A–D) Body weight (A), glycemia (B), food intake
(9 weeks of age) (C), and body composition (9 or
10 weeks of age) (D) in Vgatfl/fl/Lepob/ob and
Vgatfl/fl/AgRP-ires-cre/Lepob/ob male mice.
(E–G) Leptin infusion for 12 days at 10 weeks of
age: percent of initial body weight (E), daily food
intake (F), and glycemia (G) in Vgatfl/fl/Lepob/ob and
Vgatfl/fl/AgRP-ires-cre/Lepob/ob male mice. Error
bars are shown as SEM (n = 3–8/group).AgRP neurons coproduce and secrete AgRP, NPY, and
GABA. We therefore investigated the possible role of each these
molecules in leptin’s antidiabetic actions via AgRP neurons by
assessing the ability of recombinant leptin to correct hyperglyce-
mia in Lepob/ob mice after systematic deletion of genes pre-
venting the synthesis, release, or action of each molecule. We
found that neither global deletion of the Npy gene nor selectively
ablating GABA release by AgRP neurons via deletion of the vgat
gene affected the long-term development of diabetes or the
potency of short-term leptin infusion to normalize hyper-
glycemia. However, leptin’s glucose-lowering effects were
completely blunted in Lepob/ob mice deficient in MC4Rs, demon-Cell Reports 7, 1093–110strating the requirement of the melano-
cortin-4 receptor system. Considering
that AgRP neurons release the AgRP
neuropeptide, which acts predominantly
as a melanocortin receptor antagonist
(Corander et al., 2011), and our results
showing that AgRP neurons are both
required and sufficient in mediating
leptin’s antidiabetic actions, we conclude
that leptin exerts its effect on glucose
balance, at least in part, by decreasing
the synthesis/release of the AgRP neuro-
peptide from AgRP neurons, thus allow-
ing a-MSH-dependent activation of the
MC4R. Consistent with this conclusion,
earlier studies have suggested a role of
MC4Rs in control of glucose homeostasis
(da Silva et al., 2009; Rossi et al., 2011).
Importantly, in direct support of our
studies, deletion of the AgRP neuropep-
tide in Leprdb/db mice corrects hypergly-
cemia (Sheffer-Babila et al., 2013).
Moreover, AgRP neurons and the down-
stream melanocortin system are impor-
tant for central FGF-19 action to improve
glucose status (Marcelin et al., 2014) and
it was reported that AgRP neurons can
exert glucoregulatory actions by insulin
and ghrelin (Ko¨nner et al., 2007; Wang
et al., 2014). These results altogether
point to AgRP neurons (and specifically
the AgRP neuropeptide) serving as a
crucial node for CNS modulation ofperipheral blood glucose homeostasis by several hormonal
factors (Belgardt and Bru¨ning, 2010; Varela and Horvath, 2012).
It has been reported that animals lacking both leptin and NPY
have reduced serum glucose levels (Erickson et al., 1996a).
However, we did not find any long-term effect of NPY deletion
on the development of diabetes or in the acute glucose-lowering
effect of leptin administration to NPY//Lepob/ob mice. The
reason for the discrepancy in baseline glycemia is unclear but
may be explained by the fact that glycemia was assesses by
Erickson et al. at 16 weeks of age when double mutants were
slightly leaner compared to control animals. Our measurements
were done at 4–10 weeks of age when body weights were the3, May 22, 2014 ª2014 The Authors 1099
same. Alternatively, differences in genetic background may also
explain the divergent results on glycemia.
Leptin also has potency to fully reverse hyperglycemia in
mouse and rat models of type 1 diabetes (Chinookoswong
et al., 1999; Yu et al., 2008; Fujikawa et al., 2010). This effect is
mediated by the CNS and is independent of insulin action, thus
raising the question whether the responsible neuronal systems
and peripheral effectors are the same or divergent in obese
leptin-deficient/LepRb-deficient mice and the type 1 diabetic
models. Recently, Coppari and colleagues reported that the anti-
diabetic action of leptin in STZ-treated mice partially required
leptin receptors in POMC neurons (Fujikawa et al., 2013). They
also found that LepRb in POMC neurons was not sufficient to
reduce hyperglycemia in a similar mouse model of insulin
deficiency. These results therefore contrast the findings in the
current study. Although both studies support a role of leptin
receptors in POMC neurons in leptin’s antidiabetic action, the
reasons for the discordant results on the requirement versus
sufficiency are unclear and warrant further studies. Coppari
and colleagues further showed evidence that LepR expression
only in hypothalamic GABAergic neurons is sufficient to correct
diabetes in the insulin-deficient type 1 diabetic animal model
(Fujikawa et al., 2013) and concluded that these neurons might
well be ARCAgRP neurons, although this was not directly tested.
Experiments directly assessing the role of the melanocortin sys-
tem reported that the MC4R is required for leptin’s antidiabetic
actions in type 1 diabetic animals (STZ rats; da Silva et al.,
2009). These results combined thus support the possibility that
the same CNS systems (i.e., AgRP and POMC neurons and
the downstreammelanocortin-receptor system) play major roles
in mediating leptin’s antidiabetic actions in both type 1 and type
2 diabetic rodent models.
The study by Fujikawa et al. further reported that leptin therapy
in type 1 diabetic mice reversed the induced hyperglucagonemia
to normal levels and concluded that suppression of glucagon
therefore likely contributes, if not entirely mediates, the reversal
by leptin of the hyperglycemic state to normoglycemia. Similar
results on glucagon reduction were found in earlier studies in
leptin-treated type-1 diabetic rodent models (Yu et al., 2008; Fu-
jikawa et al., 2010). We found that expression of LepRb only in
AgRP neurons Lepdb/db mice resulted in normalization of hyper-
glucagonemia. In addition, short-term, low-dose leptin infusion
in Lepob/ob also corrected glucagon levels, concomitant with
glucose normalization. Neither of these two experiments indi-
cated effects on circulating insulin concentrations, therefore
pointing to insulin-independent processes as demonstrated in
the type 1 models. We therefore conclude that the leptin-
AgRP-MC4R axis acts to suppress glucagon, which is therefore
the likely peripheral hormone responsible for the glucose-
lowering effect of the pathway.
Besides our principal findings on glucose control by leptin, we
also provide important data on the role of specific neurons on the
control of energy balance by leptin. First, we showed that re-
expression of LepRb only in AgRP or SF1 neurons of Leprdb/db
mice reduces body weight by 15% (8 g at 12 weeks of
age), which accounts for30%of theweight difference between
Leprdb/db and lean Lepr+/+ mice (25 g). These data are in line
with the increased weight observed in animals with deletion of1100 Cell Reports 7, 1093–1103, May 22, 2014 ª2014 The AuthorsLepRb in AgRP or SF1 neurons (Dhillon et al., 2006; van de
Wall et al., 2008), altogether suggesting that both AgRP and
SF1 neurons each mediate a significant proportion of leptin’s ef-
fect on body weight. Interestingly, despite their massive obesity,
mice with re-expression of LepRb only in AgRP neurons (HA-
LepRbflox/AgRP-ires-cre/Leprdb/db) had completely normalized
food intake, thus showing a significant capability of AgRP neu-
rons to mediate long-term, leptin-dependent inhibition of caloric
intake, at least in the hyperleptinemic Leprdb/db model. These
results therefore further suggest that reduced energy expendi-
ture rather than hyperphagia is the main determinator of the
obesity in Leprdb/db mice. Indeed, when we food restricted
Leprdb/db to the caloric intake level of Lepr+/+ lean control mice
over 12 weeks, the Leprdb/db animals remained severely obese.
Leprdb/db mice expressing LepRb only in SF1 neurons had a
similar caloric intake compared to Leprdb/db mice but yet ex-
hibited a weight loss. This suggests that LepRb in SF1 neurons
plays a role in increasing energy expenditure, but not in reducing
food intake by leptin. This was also concluded from analyses of
non-Leprdb/db mice with selective deletion of LepRb in SF1
neurons (Dhillon et al., 2006).
We also report on the effects on energy homeostasis in leptin-
deficient mice lacking NPY, MC4R, or GABA release by AgRP
neurons. Deletion of NPY and MC4R in Lepob/ob mice has been
already described (Erickson et al., 1996a; Trevaskis and Butler,
2005). Supporting the findings of those studies, we did not
observe any effects of the deletion of MC4R or NPY on long-
term energy balance in our double-mutant mice. We also
investigated the role of GABA release from AgRP neurons in lep-
tin-deficient states. Based on studies reporting a function, albeit
small, of GABAergic transmission from AgRP neurons in control
of long-term body weight balance in chow-fed mice (Tong et al.,
2008;Wu et al., 2009) and evidence supporting short-term/acute
effects of AgRP-neuron-derived GABA to promote feeding (Wu
et al., 2009, Krashes et al., 2013), it was somewhat surprising
that Vgatfl/fl/AgRP-ires-cre/Lepob/ob mice entirely lacked a
body weight or feeding phenotype. Our data might suggest
that GABA release from AgRP neurons requires intact leptin
action to influence energy balance or, alternatively, compensa-
tory changes may have occurred during early development.
In conclusion, our results provide important advances in the
understanding of a neurocircuitry involved in mediating benefi-
cial antidiabetic actions of leptin. We suggest that AgRP neurons
can serve a major role in the control of glucose metabolism by
leptin in obese diabetic states. In addition, this beneficial
glucose-lowering action of leptin does not involve NPY or
GABA but instead requires the melanocortin system, suggesting
a specific role of the AgRP peptide. Finally, the suppression of
glucagon is a probable peripheral mechanism leading to
lowering of blood glucose, presumably via inhibition of hepatic
glucose production. The combined data indicate the existence
of a LepRb-AgRP-MC4R-glucagon-glucose axis.EXPERIMENTAL PROCEDURES
Animal Care
Animal care and procedures were approved by the Institutional Animal Care
and Use Committee at Beth Israel Deaconess Medical Center. Mice were
single housed at 22C–24C using a 14 hr light/10 hr dark cycle. Unless
otherwise specified, mice were fed a standard chow diet with ad libitum
access to food and water.
Generation of Transgenic Mice
HA-LepRbflox, POMC-cre, AgRP-ires-cre, SF1-cre, LepRbflox, MC4R+/,
NPY+/, and Vgatflox mice were generated as previously described (Balthasar
et al., 2004, 2005; Bjørbaek et al., 1995; Cohen et al., 2001; Dhillon et al., 2006;
Erickson et al., 1996b; Huo et al., 2009; Tong et al., 2008). Leprdb/+ (stock no.
001192) and Lepob/+ (stock no. 000696) mice were purchased from Jackson
Laboratory. To generate the HA-LepRbflox/AgRP-ires-cre/Leprdb/db or HA-
LepRbflox/SF1-cre/Leprdb/db mice, HA-LepRbflox mice were mated with
AgRP-ires-cre or SF1-cremice.HA-LepRbflox/AgRP-ires-cre orHA-LepRbflox/
SF1-cre mice were then mated with Leprdb/+ animals. HA-LepRbflox/AgRP-
ires-cre/Leprdb/db or HA-LepRbflox/SF1-cre/Leprdb/db mice were finally
obtained by mating HA-LepRbflox/AgRP-ires-cre/Leprdb/+ or HA-LepRbflox/
SF1-cre/Leprdb/+ mice with HA-LepRbflox/Leprdb/+ mice. To generate the
LepRbfl/fl/AgRP-ires-cre/Lepob/ob, LepRbfl/fl/POMC-cre/Lepob/ob, or LepRbfl/fl/
SF1-cre/Lepob/ob mice, LepRbfl/fl mice were first mated with AgRP-ires-cre,
POMC-cre, or SF1-cre mice. LepRbfl/+/AgRP-ires-cre, LepRbfl/+/POMC-cre,
or LepRbfl/+/SF1-cre mice were then mated with Lepob/+ mice. LepRbfl/fl/
AgRP-ires-cre/Lepob/ob, LepRbfl/fl/POMC-cre/Lepob/ob, or LepRbfl/fl/SF1-cre/
Lepob/ob mice were obtained by mating LepRbfl/+/AgRP-ires-cre/Lepob/+,
LepRbfl/+/POMC-cre/Lepob/+, or LepRbfl/+/SF1-cre/Lepob/+ mice with
LepRbfl/+/Lepob/+ mice. To generate the MC4R//Lepob/ob or NPY//
Lepob/ob mice, MC4R/+ or NPY/+ mice were first mated with Lepob/+ mice.
MC4R/ Lepob/ob or NPY//Lepob/ob mice were obtained by intermating
MC4R/+/Lepob/+ or NPY/+/Lepob/+ mice. To generate the Vgatfl/fl/AgRP-
ires-cre/Lepob/ob mice, Vgatfl/+ mice were first mated with AgRP-ires-cre
mice. Vgatfl/+/AgRP-ires-cremice were then mated with Lepob/+ mice. Finally,
Vgatfl/+/AgRP-ires-cre/Lepob/+ mice were mated with Vgatfl/+/Lepob/+ mice.
Littermates were used in all studies.
Body Weight and Food Intake
Daily or weekly body weight and food intake were measured as described
previously (Ziotopoulou et al., 2000).
Body Composition
Mice at 10–12 weeks of age were subjected to MRI using EchoMRI (Echo
Medical Systems) to obtain the body composition.
Leptin Administration via Miniosmotic Pumps
Mice at 8–10weeks of agewere anesthetized intraperitoneally using ketamine/
xylazine. Alzet 2002 miniosmotic pumps filled with indicated concentrations of
leptin (Dr. E. Parlow; National Institute of Diabetes and Digestive Kidney
Diseases) or PBS (placebo) were implanted subcutaneously on day 0. At
days 8–13, mice were sacrificed and blood was collected.
Blood Composition
Tail vein blood was collected at 8 a.m. ± 2 hr from ad-libitum-fed mice.
Blood glucose was assayed with OneTouch Ultra Blood Glucose Monitoring
System (Fisher Scientific). ELISAs were used to measure serum insulin and
leptin (Alpco). Serum glucagon was measured using an ELISA from R&D
Systems.
Statistical Analyses
Data are presented as means ± SEM, and significant level was set at p% 0.05.
Analyses were done using one-way ANOVA or two-way ANOVA (Bonferroni
post hoc analyses) as listed in figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2014.04.010.CACKNOWLEDGMENTS
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